Patents Assigned to Takeda Pharmaceutical Company Limited
  • Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
    Patent number: 11596671
    Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor IX variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia B. In some embodiments, the present disclosure provides methods for dosing a hemophilia B patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor IX polypeptide.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: March 7, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hanspeter Rottensteiner, Franziska Horling, Johannes Lengler, Friedrich Scheiflinger
  • Predicting outcome of treatment with an anti-?4?7 integrin antibody
    Patent number: 11596688
    Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-?4?7 antibody.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: March 7, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Maria Rosario, Timothy L. Wyant, Brihad Abhyankar
  • Nucleic acid complex
    Patent number: 11597928
    Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: March 7, 2023
    Assignees: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori Yokota, Tetsuya Nagata, Hideki Furukawa, Yasuo Nakagawa, Takatoshi Yogo, Ryosuke Tokunoh, Shigekazu Sasaki, Kosuke Hidaka, Tomohiro Seki, Kenichi Miyata, Akio Uchida
  • Stirred tank reactor systems and methods of use
    Patent number: 11591556
    Abstract: A reactor system includes a support housing having an interior surface bounding a chamber, the chamber having a vertically extending central longitudinal axis. A flexible bag is disposed within the chamber of the support housing and has an interior surface bounding a compartment. A mixing element is disposed within the compartment of the flexible bag. A drive element, such as a drive shaft, is secured the mixing element, wherein the mixing element is laterally offset from and/or is angled relative to the vertically extending central longitudinal axis of the support housing.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: February 28, 2023
    Assignees: LIFE TECHNOLOGIES CORPORATION, Takeda Pharmaceutical Company Limited
    Inventors: Kurt T. Kunas, Robert V. Oakley, Fauad F. Hasan, Michael E. Goodwin, Jeremy K. Larsen, Nephi D. Jones
  • Treatment of prostate cancer
    Patent number: 11583526
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: February 21, 2023
    Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
  • Adeno-associated virus formulations
    Patent number: 11583563
    Abstract: Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, about 0.001% (w/v) to about 0.01% (w/v) polysorbate 80 (PS80), and about 1% to about 10% (w/v) sucrose, trehalose, or combination thereof to AAV. In exemplary aspects, the pharmaceutical compositions further comprise glycine or mannitol. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a bleeding disorder in a subject, and methods of storing AAV compositions are also provided.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 21, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Christian Fiedler, Eva Fritscher, Meinhard Hasslacher, Dominik Mittergradnegger, Tanvir Tabish
  • Heterocyclic compound
    Patent number: 11584737
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 21, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
  • Formulation of an antibody and use thereof
    Patent number: 11576863
    Abstract: The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: February 14, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Markus Rast, Wolfgang Ise, Gerhard Becker, Peter Skufca, Henning Gieseler
  • HETEROCYCLIC COMPOUND
    Publication number: 20230042358
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 9, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Jun CHIBA, Yoshito TERAO, Masanori KAWASAKI
  • Compositions and methods for treating Gaucher disease
    Patent number: 11571466
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: February 7, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Peter Francis Daniel, Michael W. Heartlein
  • Nucleophilic catalysts for oxime linkage
    Patent number: 11564992
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: January 31, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Smart tourniquet
    Patent number: 11564694
    Abstract: A smart tourniquet for self-administering a medication is provided. When a patient needs to inject themselves with a medication, intravenously, called an “infusion,” the patient wears the smart tourniquet around their arm and tightens the device. While the patient is using the smart tourniquet, the device automatically records the date and time of the infusion, called a “timestamp”. The patient can also use the device to record the dosage or “number of units” taken at the time of the infusion. The smart tourniquet can store the timestamp as well as other related information as a record. At a later time, the patient can recall prior records on the smart tourniquet itself. The smart tourniquet can also be synchronized with an application and the records can be downloaded for review by the patient, nurse or doctor to render accurate and timely care.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: January 31, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Danielle Bateman, Qi-Dong Dai, Qing Gu, Seok-Choon Toh
  • Stabilized liquid and lyophilized ADAMTS13 formulations
    Patent number: 11564979
    Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: January 31, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
  • Heterocyclic compounds useful as modulators of acetylcholine receptors
    Patent number: 11560372
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, salt thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: January 24, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinobu Sasaki, Masaki Seto, Kazuaki Takami, Haruhi Ando
  • METHOD FOR CONTINUOUS PROTEIN RECOVERING
    Publication number: 20230017907
    Abstract: The present invention relates to a method for continuous recovering of a protein from a fluid, comprising precipitating the protein in the fluid and separating the precipitated protein from the fluid. The invention also provides an inclined plate settler that can be used for such continuous protein recovering.
    Type: Application
    Filed: December 10, 2020
    Publication date: January 19, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Daniel FLEISCHANDERL, Christoph DATTENBOECK, Katerina PETRUSHEVSKA-SEEBACH, Thomas GATTERNIG, Martin PURTSCHER, Alois JUNGBAUER, Hannah ENGELMAIER, Nikolaus HAMMERSCHMIDT
  • T-CELL MASTER CELL BANK
    Publication number: 20230000915
    Abstract: The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 5, 2023
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Shin KANEKO, Suguru ARIMA, Maiko TAKIGUCHI, Yoshiaki KASSAI, Akira HAYASHI
  • ANTI-PLASMA KALLIKREIN ANTIBODIES
    Publication number: 20230002509
    Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.
    Type: Application
    Filed: March 2, 2022
    Publication date: January 5, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Andrew Nixon, Jon A. Kenniston, Stephen R. Comeau
  • Sting modulator compounds, and methods of making and using
    Patent number: 11542293
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: January 3, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stepan Vyskocil, Jeffrey Ciavarri, Courtney Cullis, Dylan Bradley England, Alexandra E. Gould, Paul Greenspan, Yongbo Hu, Steven Langston, Gang Li, Hirotake Mizutani, Masanori Okaniwa
  • METHOD FOR PRODUCING T CELLS
    Publication number: 20220411752
    Abstract: Provided is an excellent method for producing an IL-4 non-secreting and IFN-? secreting (Th1-type) or IFN-? non-secreting and IL-4 secreting (Th2-type) CD4 single-positive T cell (CD4SP T cell). The method for producing the Th1-type or Th2-type CD4SP T cell of the present invention comprises a step of inducing a CD4 single-positive T cell from a hematopoietic stem cell (HSC) and/or a hematopoietic progenitor cell (HPC) substantially defective in a factor involved in IL-4 secretion or a factor involved in IFN-? secretion.
    Type: Application
    Filed: October 30, 2020
    Publication date: December 29, 2022
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Shin KANEKO, Hisashi YANO, Tokuyuki SHINOHARA
  • Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
    Patent number: 11529395
    Abstract: The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: December 20, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Miranda Chapman, Bruce Ewenstein, Bettina Ploder